CA2917050A1 - Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof - Google Patents

Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof Download PDF

Info

Publication number
CA2917050A1
CA2917050A1 CA2917050A CA2917050A CA2917050A1 CA 2917050 A1 CA2917050 A1 CA 2917050A1 CA 2917050 A CA2917050 A CA 2917050A CA 2917050 A CA2917050 A CA 2917050A CA 2917050 A1 CA2917050 A1 CA 2917050A1
Authority
CA
Canada
Prior art keywords
pyrrole
carboxylate
methyl
octahydropyrrolo
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2917050A
Other languages
English (en)
French (fr)
Inventor
Todd K. Jones
Justin S. Cisar
Cheryl A. Grice
Dong-hui WANG
Olivia D. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck La Jolla Research Center Inc
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of CA2917050A1 publication Critical patent/CA2917050A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2917050A 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof Abandoned CA2917050A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (1)

Publication Number Publication Date
CA2917050A1 true CA2917050A1 (en) 2015-01-08

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917050A Abandoned CA2917050A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Country Status (7)

Country Link
US (1) US9828379B2 (enExample)
EP (1) EP3016653A4 (enExample)
JP (1) JP6647592B2 (enExample)
CN (1) CN105517547A (enExample)
CA (1) CA2917050A1 (enExample)
MX (1) MX2015017961A (enExample)
WO (1) WO2015003002A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
CN109996790B (zh) * 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043609A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX2019008626A (es) * 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
RU2020107039A (ru) 2017-08-29 2021-09-30 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
AU2018338855B2 (en) * 2017-09-29 2022-04-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
MA52635A (fr) 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
CA3155260A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods for reducing rewarding effects of morphine without affecting its analgesic effects
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
TWI924832B (zh) * 2021-04-01 2026-05-11 日商小野藥品工業股份有限公司 Abhd6拮抗劑
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
JP7852604B2 (ja) * 2022-09-30 2026-04-28 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物
WO2024168426A1 (en) * 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
ME03452B (me) * 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011109277A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PL2900669T3 (pl) * 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Also Published As

Publication number Publication date
MX2015017961A (es) 2016-10-14
JP2016525092A (ja) 2016-08-22
EP3016653A1 (en) 2016-05-11
US9828379B2 (en) 2017-11-28
US20160137649A1 (en) 2016-05-19
JP6647592B2 (ja) 2020-02-14
CN105517547A (zh) 2016-04-20
WO2015003002A1 (en) 2015-01-08
EP3016653A4 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
US9828379B2 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
EP3271352B1 (en) Piperazine carbamates and methods of making and using same
EP3377060B1 (en) Pyrazole derivatives, processes for their preparation and uses thereof
JP7177825B2 (ja) スピロ環化合物並びにその作製及び使用方法
JP7162622B2 (ja) ピラゾールｍａｇｌ阻害剤
AU2011305568B2 (en) Imidazotriazinone compounds
AU2022203557B2 (en) Dual MAGL and FAAH inhibitors
AU2018271876B2 (en) Pyrazole MAGL inhibitors
ES2861648T3 (es) Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
WO2015179559A2 (en) Pyrazole compounds and methods of making and using same
AU2012267622B2 (en) Metabotropic glutamate receptor 5 modulators and methods of use thereof
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
US20200216445A1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
US20230183237A1 (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
EP4393919A1 (en) Lsd1 modulators
CN119255997A (zh) c-MYC mRNA翻译调节剂和其在癌症治疗中的用途
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190625

FZDE Discontinued

Effective date: 20211214